Annabel Samimy Analyst PerformanceManaging Director, Equity Research, Biopharmaceuticals at Stifel NicolausAnnabel Samimy is a stock analyst at Stifel Nicolaus focused in the medical sector, covering 16 publicly traded companies. Over the past year, Annabel Samimy has issued 16 stock ratings, including buy and hold recommendations. While full access to Annabel Samimy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Annabel Samimy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings32 Last 10 YearsBuy Recommendations89.29% 25 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution28RatingsDistribution of strong buy, buy, hold, and sell ratings by Annabel Samimy.RatingPercentageCount Strong Buy0.0%0 ratings Buy89.3%25 ratings Hold10.7%3 ratings Sell0.0%0 ratingsOut of 28 total stock ratings issued by Annabel Samimy at Stifel Nicolaus, the majority (89.3%) have been Buy recommendations, followed by 10.7% Hold.Best & Worst CallsBest Call0000.0%TXMDApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHCOct 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ87.5% of companies on NASDAQ14 companiesNYSE12.5% of companies on NYSE2 companiesAnnabel Samimy, an analyst at Stifel Nicolaus, currently covers 16 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies93.8%Manufacturing1 company6.3%Annabel Samimy of Stifel Nicolaus specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies62.5%MED PRODUCTS2 companies12.5%MED - GENERIC DRG2 companies12.5%PHARMACEUTICAL PREPARATIONS1 company6.3%MED - DRUGS1 company6.3% Annabel Samimy's Ratings History at Stifel Nicolaus Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsKMDAKamada3/11/2026Set Price Target$8.59$11.00$0.0000.00% ROIOCSOculis3/4/2026Boost Price Target$27.72$50.00Buy$0.0000.00% ROIPHATPhathom Pharmaceuticals2/26/2026Set Price Target$13.56$28.00$0.0000.00% ROIPVLAPalvella Therapeutics2/24/2026Set Price Target$119.64$250.00$0.0000.00% ROIEOLSEvolus1/13/2026Lower Price Target$5.77$17.00Buy$0.0000.00% ROITRVITrevi Therapeutics12/19/2025Boost Price Target$12.33$18.00Buy$0.0000.00% ROIRGNXREGENXBIO12/19/2025Boost Price Target$14.45$45.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics12/19/2025Boost Price Target$38.02$52.00Buy$0.0000.00% ROIMBXMBX Biosciences12/19/2025Boost Price Target$30.05$50.00Buy$0.0000.00% ROISUPNSupernus Pharmaceuticals12/19/2025Boost Price Target$50.41$55.00Hold$0.0000.00% ROIOCSOculis12/19/2025Boost Price Target$20.80$40.00Buy$0.0000.00% ROIAPLSApellis Pharmaceuticals12/19/2025Lower Price Target$24.70$48.00Buy$0.0000.00% ROILGNDLigand Pharmaceuticals12/10/2025Boost Price Target$185.83$230.00Buy$0.0000.00% ROIGPCRStructure Therapeutics12/8/2025Boost Price Target$69.98$90.00Buy$0.0000.00% ROIGPCRStructure Therapeutics12/2/2025Set Price Target$33.58$50.00$0.0000.00% ROIPVLAPalvella Therapeutics9/24/2025Boost Price Target$59.95$80.00Buy$0.0000.00% ROILGNDLigand Pharmaceuticals4/10/2025Initiated Coverage$103.85$143.00Buy$000.0000.00% ROIPVLAPalvella Therapeutics3/26/2025Initiated Coverage$27.27$45.00Buy$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
